Be prepared for biosimilars
A new US law has paved the way for biosimilar drugs. Janice A Vatland, Michael T Siekman and Chelsea A Loughran explain what pioneer and biosimilar manufacturers need to know
Perhaps the most important provision of the recently enacted health care reform act for biopharmaceutical companies has nothing to do with expanding access to medical insurance. The Biologics Price Competition and Innovation Act (Biosimilar Act) establishes a long-awaited pathway for...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.